Publications by authors named "Jonathan A Webster"

Claim this Profile
I
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.
Jonathan A Webster, Madison Reed, Hua-Ling Tsai, Philip H Imus, Douglas B Smith

Haematologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, Mark J Levis, Ivana Gojo

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, Gabriel Ghiaur, B Douglas Smith, Jonathan A Webster

Leuk Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.
Neil D Palmisiano, Ju-Whei Lee, David F Claxton, Elisabeth M Paietta, Hassan Alkhateeb, Jonathan A Webster

EJHaem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death.
Jia Jia, Wenbo Ji, Antoine N Saliba, Clifford M Csizmar, Kaiqin Ye, Jonathan A Webster

Cell Death Differ· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome heterogeneity of -mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.
Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, Jonathan A Webster, Tania Jain

Haematologica· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.
Amanda B Kagan, Dominique A Garrison, Nicole M Anders, Jonathan A Webster, Sharyn D Baker

Clin Transl Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
This CAR won't start: predicting nonresponse in ALL.
Jonathan A Webster, Leo Luznik

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Khaled Sanber, Kevin Ye, Hua-Ling Tsai, Matthew Newman, Jonathan A Webster

Leuk Lymphoma· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Jonathan A Webster, Madison Reed, Hua-Ling Tsai, Alexander Ambinder, Tania Jain

Transplant Cell Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Jonathan A Webster, Meera Yogarajah, Marianna Zahurak, Heather Symons, Amy E Dezern

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
Jonathan A Webster, Tara M Robinson, Amanda L Blackford, Erica Warlick, Anna Ferguson

Leuk Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of AML Relapse After Allo-HCT.
Jonathan A Webster, Leo Luznik, Ivana Gojo

Front Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Joshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, Dominic Moore, Karen P McKinnon, Jonathan A Webster

Blood Cancer Discov· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobile app validation: a digital health scorecard approach.
Ramy Sedhom, Michael J McShea, Adam B Cohen, Jonathan A Webster, Simon C Mathews

NPJ Digit Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.
Husheng Ding, Nicole D Vincelette, Cordelia D McGehee, Mira A Kohorst, Brian D Koh, Jonathan A Webster

Cancer Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification.
Andrew Y Li, Sarah M Kashanian, Bryan C Hambley, Kyle Zacholski, Vu H Duong, Jonathan A Webster

Biology (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
Jonathan A Webster, Leo Luznik, Hua-Ling Tsai, Philip H Imus, Amy E DeZern

Blood Adv· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.
Bryan C Hambley, Kelly J Norsworthy, Jagar Jasem, Jacquelyn W Zimmerman, Eugene Shenderov, Jonathan A Webster

Leuk Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature.
Alisha D Ware, Laura Wake, Patrick Brown, Jonathan A Webster, B Douglas Smith

AJSP Rev Rep· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia in the elderly: therapeutic options and choice.
Jonathan A Webster, Keith W Pratz

Leuk Lymphoma· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Jonathan A Webster, Raoul Tibes, Larry Morris, Amanda L Blackford, Mark Litzow

Leuk Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variations in stromal signatures in breast and colorectal cancer metastases.
Jonathan A Webster, Andrew H Beck, Mimansa Sharma, Inigo Espinosa, Britta Weigelt

J Pathol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis